Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumour Cancer

Official Title

A Phase1b/2 Study Assessing Safety and Anti-tumour Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumours


A multi-centre Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumours.

Trial Description

Primary Outcome:

  • Number of participants with treatment related adverse events as assessed by CTCAE version 4.0
  • Objective response rate of tumours using irRECIST criteria for total measureable tumour burden
  • Number of participants with treatment emergent adverse events as assessed by CTCAE version 4.0
Secondary Outcome:
  • Objective response rate of tumours using RECIST 1.1 criteria for total measurable tumour burden
  • Maximum observed concentration [Cmax] of AMG820
  • CD4, CD8, and CD68 cell numbers in pre-treatment tumour biopsy tissue
  • Minimum observed concentration [Cmin] of AMG 820
  • Area Under the Curve [AUC] of AMG820
Phase 1b is AMG 820 dose determining and aimed at assessing the safety and tolerability of the selected starting dose of AMG 820 in combination with pembrolizumab. Phase 2 of the study will further evaluate safety and tolerability and additionally test whether AMG 820 can enhance the anti-tumour activity observed historically with pembrolizumab alone and/or overcome lack of response to pembrolizumab monotherapy in subjects with select solid tumours.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society